## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.12 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-3.0% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($759.47)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Amundi Decreases Stock Position in McKesson Corporation $MCK**
- Source: MarketBeat | 20251206T080851 | Somewhat-Bullish | Relevance: 99%
- Amundi slightly decreased its stake in McKesson Corporation, selling 28,765 shares but still holding 631,431 shares valued at $445.4 million as of its most recent filing. Despite this, other institutional investors increased their positions in McKesson, and the company reported strong Q2 earnings, beating analyst expectations with $9.86 EPS and announcing a quarterly dividend of $0.82. Several analysts have raised their price targets for MCK, with a consensus "Moderate Buy" rating.

**2. McKesson's (NYSE:MCK) earnings growth rate lags the 37% CAGR delivered to shareholders**
- Source: Yahoo Finance | 20251206T140806 | Somewhat-Bullish | Relevance: 98%
-  McKesson Corporation (NYSE:MCK) has shown impressive share price growth, delivering a 363% return to shareholders over the last five years, equating to a 37% compound annual growth rate (CAGR). However, its earnings per share (EPS) growth during the same period was 20% per year, lagging behind the share price appreciation. This indicates that market sentiment towards McKesson has become more positive, as the share price has grown faster than its underlying earnings.

**3. McKesson Corporation $MCK Shares Sold by Lombard Odier Asset Management USA Corp**
- Source: MarketBeat | 20251209T133143 | Neutral | Relevance: 98%
-  Lombard Odier Asset Management USA Corp significantly reduced its stake in McKesson Corporation (NYSE:MCK) by 57.8% in the second quarter, selling over 4,200 shares. Despite this, several other institutional investors, including Norges Bank and Nuveen LLC, purchased new stakes or increased their holdings in McKesson during recent quarters. Analysts hold a "Moderate Buy" rating for McKesson with a consensus target price of $892.86.

**4. Baird Financial Group Inc. Has $28.01 Million Stock Holdings in McKesson Corporation $MCK**
- Source: MarketBeat | 20251206T085555 | Bullish | Relevance: 98%
-  Baird Financial Group Inc. increased its stake in McKesson Corporation (NYSE:MCK) by 5.7% during the second quarter, bringing their total holdings to 38,219 shares valued at $28.01 million. Other institutional investors have also adjusted their positions in MCK, which reported strong earnings, beating analyst estimates, and announced a quarterly dividend of $0.82. Analysts have set a consensus price target of $887.69 for McKesson, with an average rating of "Moderate Buy."

**5. First Trust Advisors LP Grows Position in McKesson Corporation $MCK**
- Source: MarketBeat | 20251206T093439 | Bullish | Relevance: 98%
-  First Trust Advisors LP increased its stake in McKesson Corporation by 22.7% during the second quarter, now owning 170,755 shares valued at $125.13 million. Several other hedge funds also adjusted their positions in MCK, with institutional investors collectively owning 85.07% of the company's stock. The article also touches upon recent analyst ratings, an insider stock sale, and McKesson's latest financial performance and dividend announcement.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-10 | Wells Fargo | $914 | $816 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.0% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Balance sheet: $2.3B free cash flow. Analyst sentiment positive (1 raises, avg +12%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $99.3B |
| Beta | 0.38 |
| 52W Range | $558.13 - $895.58 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 18.2 |
| Current P/E | 20.6 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -4.8% to -7.9% (-3.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 11.9pp (needs >4.0% for momentum thesis). AM_20 at -5.9% indicates price below own 20MA trend. Underperforming sector by 4.5pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-10.94), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -7.87% (CS: 4) | Weak |
| RSI_14 | 38.2 | Neutral |
| MACD Histogram | -10.94 | Bearish |
| vs SMA20 | 0.941x | Below |
| vs SMA50 | 0.981x | Below |
| vs SMA200 | 1.102x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $797.93
- **Stop Loss:** $759.47 (4.8% risk)
- **Target:** $874.85 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 13
- **Position Value:** $10,373.09
- **Portfolio %:** 10.37%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*